Not a Cholesterol Drug: The Full Picture on What Statins Actually Do
Statins are not cholesterol drugs. They are mevalonate pathway inhibitors. That distinction changes everything about how we should evaluate their effects, because the mevalonate pathway produces far more than cholesterol — it produces CoQ10, vitamin K2, steroid hormones, vitamin D precursors, dolichols, heme A, and the prenyl groups required for dozens of cellular signaling proteins. Blocking the pathway at HMG-CoA reductase does not selectively lower one number on a lipid panel. It reduces substrate for mitochondrial energy production, vascular calcium regulation, hormone synthesis, protein glycosylation, and cellular signaling. This paper examines what happens to each of those downstream outputs when the pathway is chronically suppressed.
This is not an argument that statins help no one. For patients who have already had a cardiovascular event, the evidence for benefit is meaningful and we do not dismiss it. What we are examining is the broader claim that these drugs are simple, well-understood, and essentially safe tools for cardiovascular protection. That claim cannot survive contact with the full literature.
The Mevalonate Pathway: A Hub, Not a Pipeline
HMG-CoA reductase converts HMG-CoA to mevalonate, the first committed step of the mevalonate pathway. Everything downstream depends on the rate at which this enzyme operates. Cholesterol is synthesized from mevalonate, yes, but so is an entire family of molecules the body uses for functions entirely unrelated to lipid transport. The non-sterol isoprenoids produced downstream include coenzyme Q10 (ubiquinone), dolichols, heme A, isopentenyl tRNA, and the prenyl intermediates farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are required for the post-translational modification of dozens of signaling proteins.
The pathway also produces the substrate for steroid hormone synthesis. Cholesterol is the structural precursor for every steroid hormone in the human body: cortisol, testosterone, estrogen, progesterone, DHEA, aldosterone, and vitamin D. Blocking the mevalonate pathway upstream of all of these branches does not selectively target LDL particles. It reduces the raw material available to every tissue that depends on the pathway's outputs.
Coenzyme Q10: Powering the Heart You Are Trying to Protect
CoQ10 is synthesized from farnesyl pyrophosphate, an intermediate deep in the mevalonate pathway. Its primary role is as an electron shuttle in the mitochondrial respiratory chain. Without adequate CoQ10, the electron transport chain operates less efficiently, reactive oxygen species accumulate, and the tissues with the highest energy demands suffer most. The heart muscle is among those tissues.
The depletion of circulating CoQ10 by statin therapy has been documented consistently since at least 1990. Studies have shown serum CoQ10 reductions ranging from 16 to 49 percent depending on statin type and dose. A 2014 review described the situation plainly: statin-induced CoQ10 depletion is well documented in animal and human studies with detrimental cardiac consequences in both settings. The depletion is dose-related and more pronounced in populations with pre-existing CoQ10 deficiency, including the elderly and those with heart failure — the exact populations most commonly prescribed long-term statin therapy.
The clinical consequence under investigation is statin-associated muscle symptoms (SAMS). The incidence figures diverge dramatically based on who is funding the research. Industry-funded trials report SAMS below 1%; non-industry-funded trials report 10 to 25%; some observational studies place the figure as high as 60%. That gap across funding sources is not a statistical nuisance. It is a measurement problem that has not been resolved and that deserves to be named rather than averaged away.
The mechanism is supported by tissue-level evidence. Muscle biopsies from SAMS patients show ragged red fibers, increased intramuscular lipid, and reduced cytochrome oxidase staining, all consistent with mitochondrial dysfunction. A 2019 study in Aging found that pharmacological CoQ10 deprivation via statins triggers intracellular oxidative stress and mitochondrial dysfunction in human cells above a concentration threshold. A 2023 meta-analysis of RCTs found a significant reduction in SAMS pain intensity after CoQ10 supplementation.
It bears noting that primary CoQ10 deficiency without any drug involvement is associated with heart failure, nephrotic syndrome, neuropathy, and muscular and neurological disorders. We prescribe statins to people at risk of heart failure without routinely monitoring the CoQ10 status that the drug is known to deplete.
Vitamin K2: The Calcium Director We Are Disabling
Vitamin K2 (MK-4 isoform) is synthesized in extrahepatic tissues including the arterial wall, brain, and pancreas. The synthesis requires geranylgeranyl pyrophosphate as a precursor. When statin therapy reduces GGPP availability, MK-4 synthesis falls with it.
K2 activates Matrix Gla Protein (MGP) through carboxylation. MGP is the most potent known inhibitor of vascular calcification. When K2 is sufficient, active MGP binds calcium in arterial tissue and escorts it toward bone. When K2 is insufficient, MGP remains inactive and calcium accumulates in soft tissue, including the coronary arteries.
Research has traced the biochemical chain: statins reduce mevalonate → reduce GGPP → reduce substrate for UBIAD1, the enzyme responsible for MK-4 biosynthesis. Animal studies using atorvastatin found reductions of approximately 45% in kidney MK-4 levels.
A 2021 clinical study found significantly elevated markers of vitamin K deficiency in statin users, including elevated uncarboxylated osteocalcin. Critically, a positive correlation was found between uncarboxylated osteocalcin and coronary artery calcium scores in statin users but not in non-users — exactly the signal predicted by the biochemical mechanism.
The Calcification Paradox
Statins measurably increase coronary artery calcification. A 2023 retrospective study of 1,181 U.S. veterans found a significant, dose-dependent association between statin duration and coronary calcium score. Compared to no statin use, the odds ratio for severe calcification was:
| Statin Duration | Odds Ratio for Severe Calcification |
|---|---|
| 0-5 years | 1.71 |
| 5-10 years | 2.80 |
| >10 years | 5.30 |
A 2023 meta-analysis of 41 studies found a pooled odds ratio of 2.11 for coronary calcification in statin users. The standard response is that statin-induced calcification may represent denser, more stable deposits. That interpretation may have merit. What it should not do is cause us to stop noticing that a drug prescribed to protect coronary arteries is associated, in a dose-dependent and time-dependent way, with a fivefold increase in severe coronary calcification with long-term use.
The Hormone Cascade: What Happens Downstream of Cholesterol
Cholesterol is the structural precursor for every steroid hormone: cortisol, testosterone, estrogen, progesterone, DHEA, aldosterone, and the hormonal form of vitamin D. When statin therapy reduces cholesterol synthesis, it reduces substrate availability for one of the most consequential biosynthetic pathways in the body.
A 2013 meta-analysis of RCTs found that statins produce small but statistically significant reductions in testosterone. A subsequent meta-analysis of 21 studies (~10,000 patients) confirmed statistically significant reductions in total testosterone. A MESA study found 11% lower SHBG levels among statin users.
The mechanisms are biochemically coherent: statins suppress de novo cholesterol synthesis in the testes, impairing substrate availability. Simvastatin inhibits CYP17A1 expression in a dose-dependent manner. There is no biochemical reason that statin-induced substrate reduction would selectively affect the gonads while leaving the adrenals untouched.
Vitamin D: Another Cholesterol Derivative
Vitamin D synthesis begins with 7-dehydrocholesterol, a direct derivative of cholesterol converted to pre-vitamin D3 in the skin upon UV exposure. When statin therapy reduces cholesterol synthesis, it reduces the pool of available substrate. In a population already broadly vitamin D insufficient, prescribing a drug that reduces the substrate for its synthesis is a concern that has received almost no clinical attention.
Diabetes: A Side Effect That Became a Label Warning
In 2012, the FDA added a warning to statin labels noting increased risk of type 2 diabetes. This was added after decades of widespread use, when the signal became too consistent to ignore.
A 2024 Lancet Diabetes meta-analysis confirmed that statins cause a moderate, dose-dependent increase in new diabetes diagnoses. A clinical trial using gold-standard methods found that high-intensity atorvastatin produces measurable increases in insulin resistance accompanied by compensatory increases in insulin secretion.
Several mechanisms have been identified:
- Statins reduce GLUT-4 expression in muscle and adipose tissue
- They impair calcium signaling in pancreatic beta cells required for insulin secretion
- They activate hepatic gluconeogenesis through PEPCK and G6Pase
- They reduce isoprenylation of RabGTPases required for GLUT-4 trafficking
A striking finding from Mendelian randomization studies: genetic polymorphisms that reduce HMG-CoA reductase activity are associated with increased body weight, insulin resistance, and increased diabetes risk. This is not the drug interacting badly with a susceptible subgroup — this is the core mechanism of the drug, applied genetically, producing diabetogenic effects.
The Numbers We Are Not Told: Absolute Risk and NNT
When trials report a 25-30% reduction in cardiovascular events, that is a relative risk reduction. The number needed to treat (NNT) converts this into something more honest.
| Population | Outcome | 5-Year NNT |
|---|---|---|
| Primary prevention (low risk) | Prevent 1 nonfatal heart attack | 217 |
| Primary prevention (low risk) | Prevent 1 stroke | 313 |
| Expanded guideline threshold | Prevent 1 event | 400 |
| Primary prevention | Overall mortality benefit | No significant benefit |
For every 217 people who take a statin for 5 years, 216 experience whatever side effects they experience and receive no benefit. The 217th avoids a nonfatal heart attack. In patients without established heart disease, there is no statistically significant overall mortality benefit.
Most statin prescriptions are written in primary prevention, for patients who have not had a cardiovascular event. Patients, when given absolute rather than relative numbers, assess the trade-off differently than the guidelines do.
The Brain: A Separate Cholesterol Economy
The brain accounts for roughly 20% of the body's cholesterol while representing only 2% of its mass. That cholesterol is synthesized locally and is essential for myelin formation, synaptic function, neurotransmitter receptor expression, and membrane integrity. The blood-brain barrier is largely impermeable to LDL particles — the brain maintains its own independent cholesterol economy.
Lipophilic statins (simvastatin, atorvastatin) passively diffuse across the blood-brain barrier and suppress cholesterol synthesis locally within the brain. Hydrophilic statins remain primarily hepatoselective. This distinction is not routinely discussed when a prescription is written.
In 2012, the FDA listed memory loss, forgetfulness, amnesia, memory impairment, and confusion as potential adverse effects of all statins. A UK Biobank study of 147,000+ participants found that reduced LDL may be detrimental to cognition, with LDL mediating more than 50% of the observed association between statin use and cognitive performance. Both very high and very low LDL are associated with worse cognitive outcomes — a U-shaped relationship.
The Forgotten Outputs: Dolichols and Heme A
Dolichols are long-chain isoprenoid alcohols synthesized from farnesyl pyrophosphate. Dolichol phosphate is the carrier molecule required for N-linked glycosylation — the process by which oligosaccharide chains are attached during protein synthesis. N-glycosylation is required for correct protein folding, cell surface receptor function, immune recognition, enzyme activity, and membrane protein integrity.
Heme A serves as a prosthetic group in Complex IV of the mitochondrial electron transport chain (cytochrome c oxidase). Complex IV is the terminal enzyme of the respiratory chain — the step where electrons are transferred to oxygen to form water, coupled to ATP synthesis. Heme A synthesis requires farnesyl pyrophosphate. Experimental work has documented that statins disturb mitochondrial complex function, consistent with this biochemical prediction.
These are predicted consequences of blocking a pathway that produces them. They have not been evaluated in any systematic way. Their absence from clinical discussion is not evidence that they are not occurring — it is evidence that we have not looked.
Signaling Proteins: When the Post Office Stops Delivering
The prenyl intermediates FPP and GGPP are added post-translationally to small GTPase proteins including Ras, Rho, Rac, and Rab families. Without this lipid modification, these proteins cannot anchor to cell membranes and cannot function. They govern cell proliferation, immune activation, cytoskeletal organization, vascular tone, and gene expression.
The same mechanism responsible for statins' alleged "pleiotropic" anti-inflammatory benefits is also responsible for effects on signaling pathways we may not be monitoring. The diabetes mechanism connects here directly: impaired prenylation of RabGTPases leads to defective GLUT-4 trafficking. You cannot suppress FPP and GGPP synthesis and selectively keep only the effects you wanted.
The Funding Gap
The SAMS incidence discrepancy — from below 1% to over 60% depending on funding source — is not unique to statins but is worth naming specifically given the scale, the importance of the drugs, and the degree to which treatment guidelines have been built predominantly on industry-sponsored evidence.
A patient making an informed decision about taking a drug every day for decades deserves to know that the side effect rates in guideline-forming studies may not reflect their actual experience. The controlled trial environment is designed to measure efficacy. It is poorly designed to capture actual side effect incidence.
Conclusion
The mevalonate pathway is a hub, not a pipeline. Blocking it at HMG-CoA reductase does not selectively lower one number on a panel. It reduces substrate for mitochondrial energy production, vascular calcium regulation, steroid hormone synthesis, protein glycosylation, cellular signaling, and several others. The CoQ10 depletion is real and documented. The K2 disruption may explain the calcification increase. The testosterone signal is consistent across meta-analyses. The diabetes risk is acknowledged by the FDA. The NNT in primary prevention is large enough that most people who take the drug receive no measurable benefit.
We have been focused on one number while dozens of downstream effects have accumulated in patients who were told they were taking a simple cholesterol drug. Renaming the intervention accurately — not as a cholesterol drug but as a mevalonate pathway inhibitor — would not change the pharmacology. It would change the questions we are obligated to ask.
